Compare ING Groep NV (ING) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ING Groep NV vs Summit Therapeutics Inc — how do they compare? ING Groep NV trades at $35.34 (market cap $101.22B), while Summit Therapeutics Inc trades at $15.1 (market cap $12.06B). The key difference: ING Groep NV is far larger — about 8.4× Summit Therapeutics Inc's market cap, and ING Groep NV pays a 3.73% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ING | SMMT | |
|---|---|---|
Market Cap | $101.22B | $12.06B |
Sector | Financials | Health |
52-Week High | $35.92 | $26.98 |
52-Week Low | $23.66 | $12.55 |
Dividend Yield | 3.73% | — |
Enterprise Value | — | $11.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ING trades at $35.66, up 1.19% today, with a bullish technical signal and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $0.79 exceeding the $0.75 forecast. Revenue growth is steady, reaching $22.90B in 2025, and the company recently raised its 2026-2027 outlook, driven by robust net interest income and lending growth. A dividend of $0.46 per share is scheduled for payment on August 17, 2026.
The outlook for ING is positive, supported by upward earnings revisions, a favorable valuation with a P/E of 13.24, and institutional bullishness. Key risks include persistent negative operating cash flows and sensitivity to interest rate changes. The stock's momentum and fundamental strength present a compelling case for growth-oriented investors, though cash flow trends warrant monitoring.
Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.
The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
